OncoCyte Corporation (OCX)
NASDAQ: OCX
· Real-Time Price · USD
3.20
0.47 (17.22%)
At close: Jun 17, 2025, 3:59 PM
OncoCyte Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 2.14M | 1.49M | 115K | 104K | 176K | 314K | 429K | 463K | 297K | -3.55M | 1.02M | 2.07M | 1.42M | 3.59M | 984K | 2.03M | 1.12M |
Cost of Revenue | 813K | 511K | 65K | 54K | 511K | 409K | 181K | 191K | 287K | -5.55M | 2.19M | 2.38M | 1.96M | 2.22M | 1.85M | 2.42M | 1.04M |
Gross Profit | 1.32M | 595K | 50K | 50K | -335K | -95K | 248K | 272K | 10K | 2M | -1.17M | -314K | -533K | 1.37M | -866K | -394K | 79K |
Operating Income | -6.8M | -33.63M | -13.52M | -4.63M | -5.79M | -5M | -6.51M | -8.29M | -6.22M | 9.68M | -9.22M | -8.56M | -9.89M | -35.68M | -13.6M | -13.57M | -11.36M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | 117K | n/a | n/a | 12K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -6.67M | -33.51M | -13.49M | -4.53M | -9.13M | -15.99M | -6.49M | -8.33M | 5.96M | 9.31M | -9.33M | -8.3M | -10.29M | -35.79M | -13.8M | -12.29M | -11.48M |
Net Income | -6.67M | -33.51M | -13.49M | -4.53M | -9.13M | -15.99M | -6.49M | -8.33M | 2.4M | -45.34M | -9.45M | -8.04M | -10.69M | -35.88M | -13.8M | -10.49M | -3.92M |
Selling & General & Admin | 4.32M | 3.4M | 3.61M | 3.26M | 3.52M | 2.39M | 3.2M | 3.85M | 4.11M | -4M | 9.21M | 9.03M | 8.89M | 7.45M | 8.43M | 10.61M | 7.02M |
Research & Development | 2.92M | 1.92M | 2.82M | 2.45M | 1.93M | 2.55M | 2.19M | 2.44M | 2.13M | -7.82M | 4.42M | 5.57M | 5.13M | 4.59M | 3.14M | 2.54M | 3.36M |
Other Expenses | 66K | 28.57M | 7.14M | n/a | n/a | -22K | -4K | -16K | 50K | n/a | 62K | n/a | -36K | -47K | -8K | 16K | 2K |
Operating Expenses | 7.31M | 34.22M | 13.56M | 5.71M | 5.45M | 4.9M | 5.38M | 6.27M | 6.23M | -11.82M | 13.63M | 14.61M | 14.02M | 12.04M | 11.57M | 13.14M | 10.38M |
Interest Expense | -29K | 30K | 31K | 8K | 15K | 160K | 117K | 14K | 11K | 12K | 14K | 21K | 30K | 42K | 50K | 49K | 68K |
Selling & Marketing Expenses | 1.21M | 238K | 1.04M | 853K | 84K | 107K | 713K | 81K | 695K | -589K | 407K | 3.52M | 3.24M | 3.31M | 2.93M | 2.67M | 2.25M |
Cost & Expenses | 8.12M | 36.42M | 13.63M | 5.77M | 5.96M | 5.31M | 5.57M | 6.46M | 6.52M | -17.37M | 15.82M | 16.99M | 15.97M | 14.26M | 13.42M | 15.57M | 11.42M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 2.93M | n/a | 112K | -262K | 396K | 97K | 42K | -1.79M | -7.56M |
Shares Outstanding (Basic) | 256.94K | 13.07M | 13.71M | 12.87M | 8.26M | 8.26M | 8.26M | 7.11M | 5.96M | 5.94M | 5.93M | 5.65M | 4.61M | 4.55M | 4.57M | 4.49M | 4.11M |
Shares Outstanding (Diluted) | 256.94K | 13.07M | 13.71M | 12.87M | 8.26M | 8.26M | 8.26M | 7.11M | 5.96M | 5.94M | 5.93M | 5.65M | 4.61M | 4.61M | 4.57M | 4.49M | 4.11M |
EPS (Basic) | -25.96 | -1.93 | -0.98 | -0.36 | -1.1 | -1.94 | -0.79 | -1.17 | 0.40 | -7.64 | -1.59 | -1.42 | -2.32 | -7.88 | -3.02 | -2.34 | -0.95 |
EPS (Diluted) | -25.96 | -1.93 | -0.98 | -0.36 | -1.1 | -1.94 | -0.79 | -1.17 | 0.40 | -7.64 | -1.59 | -1.42 | -2.32 | -7.78 | -3.02 | -2.34 | -0.95 |
EBITDA | -6.8M | -32.92M | -13.52M | -4.2M | -8.78M | -4.73M | -4.7M | -7.88M | -5.75M | -4.73M | -5.92M | -6.5M | -13.37M | -34.49M | -12.51M | -10.96M | -10.87M |
EBIT | n/a | -33.48M | -13.46M | -4.52M | -9.11M | -7.44M | -5.12M | -8.32M | 5.97M | 9.32M | -7.29M | -7.86M | -3.38M | -35.75M | -13.75M | -12.24M | -11.41M |
Depreciation & Amortization | n/a | 563K | 340K | 326K | 335K | 314K | 426K | 457K | 472K | 1.28M | 1.37M | 1.36M | 1.22M | 1.25M | 1.25M | 1.28M | 546K |